ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine. The treatment consists of an intratumoral injection of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (AdV-tk) followed by valacyclovir, an anti-herpetic prodrug. Initial local cytotoxicity is mediated by the nucleoside analog generated through phosphorylation of the prodrug. Cell death via necrosis and apoptosis, viral factors that stimulate the innate immune system, and the acute inflammation from surgical debulking attract and activate antigen-presenting cells that incorporate and present tumor-associated antigens to T cells. This stimulates T-cell proliferation and interleukin 2 production, which generates a systemic anti-tumor immune response.
Advantagene is assessing whether adding ProstAtak (AdV-tk + valacyclovir) to radiotherapy and androgen deprivation therapy (ADT) can improve the recurrence rate in patients treated for intermediate- or high-risk localized prostate cancer. In this setting, ProstAtak’s main competitors will be pharmacological ADTs – gonadotropin-releasing hormone (GnRH)/luteinizing hormone-releasing hormone (LHRH) analogs. ProstAtak will only be approved for use in the US market, meaning it will miss out on uptake and sales in the lucrative five major EU markets (France, Germany, Italy, Spain, and the UK) and Japan.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 ProstAtak : Prostate cancer
LIST OF FIGURES
9 Figure 1: ProstAtak for prostate cancer – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of ProstAtak in prostate cancer
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of ProstAtak in prostate cancer
LIST OF TABLES
4 Table 1: ProstAtak drug profile
6 Table 2: ProstAtak Phase III trial in prostate cancer
8 Table 3: ProstAtak Phase II data in prostate cancer
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.